Hemab Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference
Hemab Therapeutics (Nasdaq: COAG), a clinical-stage biotech focused on blood coagulation disorders, will participate in the 2026 Jefferies Global Healthcare Conference in New York.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Hemab Therapeutics (Nasdaq: COAG), a clinical-stage biotech focused on blood coagulation disorders, will participate in the 2026 Jefferies Global Healthcare Conference in New York.
A fireside chat is scheduled for Thursday, June 4, 2026 at 9:20 AM ET, with a live webcast and replay available on Hemab’s investor website.
Details
News Market Reaction – COAG
On May 27, the day this news came out, COAG closed 2.73% above the previous close.
Data tracked by StockTitan Argus for the May 27 session.
Key Figures
- Conference date
- June 4, 2026
- Jefferies Global Healthcare Conference fireside chat
- Presentation time
- 9:20 AM ET
- Jefferies Global Healthcare Conference fireside chat
Historical Context
-
Reported Q1 results with cash runway and outlined clinical and financing milestones.
-
Closed upsized IPO at $18 per share with $346.7M gross proceeds and Nasdaq listing.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass. and COPENHAGEN, Denmark, May 27, 2026 (GLOBE NEWSWIRE) -- Hemab Therapeutics (Nasdaq: COAG), a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience, today announced that members of the Hemab Therapeutics management team will present and host investor meetings at the 2026 Jefferies Global Healthcare Conference.
2026 Jefferies Global Healthcare Conference
Fireside Chat: Thursday, June 4, 2026 at 9:20 AM ET
Location: New York, NY
A live webcast of the fireside chat will be available for replay under “Events & Presentations” section in the Investors section of Hemab Therapeutics’ website at hemab.com.
About Hemab Therapeutics
Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience. Hemab’s mission is to discover, develop, and commercialize innovative therapies for the millions of patients worldwide suffering from serious bleeding and thrombotic diseases. Hemab is building a franchise of innovative therapeutics designed to address critical gaps in the treatment of coagulation disorders, including sutacimig (HMB-001), a bispecific antibody in clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Factor VII deficiency, and HMB-002, a monovalent antibody in clinical development for the prophylactic treatment of Von Willebrand Disease.
Learn more at hemab.com. Follow us on LinkedIn, Facebook, Instagram, and X.
Media:
Deerfield
Peg Rusconi
peg.rusconi@deerfieldgroup.com
Investors:
Hemab Therapeutics
Mads Behrndt
investors@hemab.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.